Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FBIO

FBIO - Fortress Biotech Inc Stock Price, Fair Value and News

$3.38-0.08 (-2.31%)
Market Closed

34/100

FBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

FBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.75

Target 3M

$3.22

Target 6M

$3.06

FBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FBIO Price Action

Last 7 days

-2.3%

Last 30 days

-5.6%

Last 90 days

31.5%

Trailing 12 Months

88.8%

FBIO RSI Chart

FBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FBIO Valuation

Market Cap

104.8M

Price/Earnings (Trailing)

26.28

Price/Sales (Trailing)

1.68

EV/EBITDA

-0.29

Price/Free Cashflow

-1.58

FBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.75

Target 3M

$3.22

Target 6M

$3.06

FBIO Fundamentals

FBIO Revenue

Revenue (TTM)

62.3M

Rev. Growth (Yr)

20.52%

Rev. Growth (Qtr)

7.42%

FBIO Earnings

Earnings (TTM)

4.0M

Earnings Growth (Yr)

145.47%

Earnings Growth (Qtr)

-62.22%

FBIO Profitability

EBT Margin

-116.14%

Return on Equity

7.14%

Return on Assets

2.2%

Free Cashflow Yield

-63.11%

FBIO Investor Care

Shares Dilution (1Y)

62.83%

Diluted EPS (TTM)

-0.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202557.8M59.3M62.3M0
202485.1M82.6M62.5M57.7M
202364.2M62.7M81.0M84.5M
202281.1M82.2M77.6M75.7M
202144.3M52.7M64.3M68.8M
202043.1M43.3M43.0M45.6M
201927.5M29.9M34.5M36.6M
2018152.9M67.1M25.4M26.9M
201720.4M110.8M156.7M149.8M
20161.0M3.3M4.2M18.3M
2015000863.0K
20140000
20130000
Get all data in R, Python etc through our Historical Stock Data APIs

About Fortress Biotech Inc

FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
 CEO
 WEBSITEfortressbiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES187

Fortress Biotech Inc Frequently Asked Questions

FBIO is the stock ticker symbol of Fortress Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Fortress Biotech Inc is 104.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FBIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether FBIO is over valued or under valued. Whether Fortress Biotech Inc is cheap or expensive depends on the assumptions which impact Fortress Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FBIO.

As of Wed Jan 28 2026, FBIO's PE ratio (Price to Earnings) is 26.28 and Price to Sales (PS) ratio is 1.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FBIO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Fortress Biotech Inc has provided -0.213 (multiply by 100 for percentage) rate of return.